Froehner Michael, Koch Rainer, Farahzadi Samaneh, Heberling Ulrike, Borkowetz Angelika, Twelker Lars, Baretton Gustavo B, Wirth Manfred P, Thomas Christian
Department of Urology, University Hospital "Carl Gustav Carus", Technische Universität Dresden, Dresden, Germany,
Department of Medical Statistics and Biometry, University Hospital "Carl Gustav Carus", Technische Universität Dresden, Dresden, Germany.
Urol Int. 2019;103(4):427-432. doi: 10.1159/000500961. Epub 2019 Oct 29.
The aim of this study was to determine prognostic factors and to provide long-term mortality data in patients with positive lymph nodes at the time of radical prostatectomy in a sample with long-term follow-up.
A total of 527 patients with complete data sets treated in the years 1992-2014 were studied. The median follow-up was 7.2 years. The median number of removed lymph nodes was 15. Age, year of surgery, Gleason score, local tumor stage, prostate-specific antigen level, lymph node density, lymph node count and the number of positive lymph nodes were included in multivariable competing risk analyses with prostate cancer mortality as endpoint.
After 20 years, 28% of patients (95% CI 20-36%) died from non-prostate cancer (competing) causes, whereas 29% (95% CI 23-36%) died from prostate cancer. Only lymph node density (stratified by the median of 11.1%; hazard ratio [HR] 1.66, 95% CI 1.04-2.64, p = 0.0340) and Gleason score (8-10 vs. <8: HR 5.97, 95% CI 3.18-11.23, p < 0.0001) were independent predictors of prostate cancer mortality. Patients with a Gleason score <8 and a lymph node density < median had a 20-year prostate cancer mortality of only 5% (95% CI 0-10%), whereas this rate in patients with Gleason score 8-10 and a lymph node density ≥ median was 44% (95% CI 32-56%), p < 0.0001.
Mortality in patients with positive lymph nodes was determined by tumor aggressiveness and the relative extent of spread; neither the year of surgery nor the number of removed lymph nodes was associated with outcome. Patients with a lymph node density of <11.1% and a Gleason score <8 had an excellent long-term outcome.
本研究的目的是确定预后因素,并在长期随访的样本中提供根治性前列腺切除时淋巴结阳性患者的长期死亡率数据。
对1992年至2014年期间接受治疗的527例具有完整数据集的患者进行研究。中位随访时间为7.2年。切除淋巴结的中位数为15个。年龄、手术年份、Gleason评分、局部肿瘤分期、前列腺特异性抗原水平、淋巴结密度、淋巴结计数和阳性淋巴结数量被纳入以前列腺癌死亡率为终点的多变量竞争风险分析。
20年后,28%的患者(95%可信区间20 - 36%)死于非前列腺癌(竞争)原因,而29%(95%可信区间23 - 36%)死于前列腺癌。只有淋巴结密度(按中位数11.1%分层;风险比[HR] 1.66,95%可信区间1.04 - 2.64,p = 0.0340)和Gleason评分(8 - 10分与<8分:HR 5.97,95%可信区间3.18 - 11.23,p < 0.0001)是前列腺癌死亡率的独立预测因素。Gleason评分<8分且淋巴结密度<中位数的患者20年前列腺癌死亡率仅为5%(95%可信区间0 - 10%),而Gleason评分8 - 10分且淋巴结密度≥中位数的患者这一比例为44%(95%可信区间32 - 56%),p < 0.0001。
淋巴结阳性患者的死亡率由肿瘤侵袭性和相对扩散程度决定;手术年份和切除淋巴结数量均与预后无关。淋巴结密度<11.1%且Gleason评分<8分的患者长期预后良好。